Marek Wardęcki

966 citations
26 papers · 721 · h-index 11

Impact in

  • Endocrinology, Diabetes and Metabolism top 2%
    • Diabetes Management and Research
    • Diabetes Treatment and Management
    • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Hematology top 10%
    • Blood groups and transfusion
    • Platelet Disorders and Treatments

Papers in

Co-authors
Richard M. Bergenstal (6 shared papers)Matthew C. Riddle (6 shared papers)Isabel Muehlen-Bartmer (6 shared papers)M. Ziemen (6 shared papers)Hannele Yki‐Järvinen (3 shared papers)Emmanuelle Boëlle (1 shared paper)Geremia B. Bolli (5 shared papers)H Yki-Järvinen (2 shared papers)
Journals
Blood (8 papers)Diabetes Technology & Therapeutics (3 papers)Diabetes Care (3 papers)Canadian Journal of Diabetes (2 papers)EClinicalMedicine (2 papers)
Partner nations
United StatesFranceUnited Kingdom

In The Last Decade

Marek Wardęcki

25 papers receiving 699 citations

Peers

Marek Wardęcki
Comparison fields: 5 of 36
  • Endocrinology, Diabetes and Metabolism 482
  • Hematology 121
  • Surgery 127
  • Genetics 75
  • Genetics 24
Replace Parastoo Dinyari with:
Parastoo Dinyari Canada
Krystyna Jedynasty Poland
Nunzia Brusca Italy
Muhammad M. Hafiz United States
Taylor M. Triolo United States
Silvia Capriello Italy
Francesca Di Candia Italy
Ediz Yeşilkaya Türkiye
Rose Girgis Canada
Shannon Fourtner United States
Marek Wardęcki relative to Parastoo Dinyari Canada Parastoo Dinyari's profile →
Citations per field
00.5×10×20×26×
Parastoo Dinyari · 1×
Citations per year

Countries citing papers authored by Marek Wardęcki

Since Specialization
Citations

This map shows the geographic impact of Marek Wardęcki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Wardęcki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Wardęcki more than expected).

Fields of papers citing papers by Marek Wardęcki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marek Wardęcki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Wardęcki. The network helps show where Marek Wardęcki may publish in the future.

Co-authors

The 25 scholars most cited alongside Marek Wardęcki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marek Wardęcki Line = papers co-authored together Marek Wardęcki links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#Work
1
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
Diabetes Care ·Hannele Yki‐Järvinen, Richard M. Bergenstal, M. Ziemen, Marek Wardęcki, Isabel Muehlen-Bartmer, Emmanuelle Boëlle, Matthew C. Riddle
2014218
2
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial
Diabetes Care ·Julio Rosenstock, Bruno Guerci, M Hanefeld, Sandro Gentile, Ronnie Aronson, Francisco J. Tinahones, Christine Roy-Duval, Elisabeth Souhami, Marek Wardęcki, Jenny Ye, Riccardo Perfetti, Simon Heller
2016109
3
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension
Diabetes Obesity and Metabolism ·H Yki-Järvinen, Richard M. Bergenstal, Geremia B. Bolli, M. Ziemen, Marek Wardęcki, Isabel Muehlen-Bartmer, M. Maroccia, Matthew C. Riddle
2015104
4
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
Blood ·Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Junichi Nishimura, Josephine M. I. Vos, Michael Storek, Nancy Wong, Parija Patel, Xiaoyu Jiang, Deepthi S. Vagge, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome
202273
5
Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin- naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial
Diabetes & Metabolism ·Geremia B. Bolli, Matthew C. Riddle, Richard M. Bergenstal, Marek Wardęcki, Harmonie Goyeau, Philip Home
201743
6
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes
Diabetes Technology & Therapeutics ·Matthew C. Riddle, Geremia B. Bolli, Philip Home, Richard M. Bergenstal, M. Ziemen, Isabel Muehlen-Bartmer, Marek Wardęcki, Laetitia Vinet, N. Jeandidier, Hannele Yki‐Järvinen
201636
7
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)
Diabetes Technology & Therapeutics ·Satish K. Garg, Karin Wernicke‐Panten, Marek Wardęcki, Daniel Kramer, François Delalande, Edward Franek, Karita Sadeharju, Travis Monchamp, B.N. Mukherjee, Viral N. Shah
201918
8
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease
American Journal of Hematology ·Alexander Röth, Wilma Barcellini, Shirley D’Sa, Yoshitaka Miyakawa, Catherine M. Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Ilene C. Weitz, Ronnie Yoo, Deepthi Jayawardene, Deepthi S. Vagge, K. Kralova, Frank Shafer, Marek Wardęcki, Michelle Lee, Sigbjørn Berentsen
202318
9
Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
Diabetes Care ·Thomas Danne, William V. Tamborlane, Oleg Malievsky, Denise Reis Franco, Tomoyuki Kawamura, Marek Demissie, Elisabeth Niemoeller, Harmonie Goyeau, Marek Wardęcki, Tadej Battelino
202017
10
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study
Blood ·Shirley D’Sa, Josephine M. I. Vos, Wilma Barcellini, Marek Wardęcki, Laurent Perrin, Graham Barker, Moshe Zilberstein, Michael Storek, Timothy Y. Chow, Alexander Röth
202314
11
Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study
European Journal Of Haematology ·Alexander Röth, Catherine M. Broome, Wilma Barcellini, Bernd Jilma, Quentin A. Hill, David Cella, Tor Henrik Anderson Tvedt, Masaki Yamaguchi, Michelle Lee, Frank Shafer, Marek Wardęcki, Xiaoyu Jiang, Parija Patel, Florence Joly, Ilene C. Weitz
202210
12
Less Nocturnal Hypoglycemia and Weight Gain with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal Insulin with OADs (EDITION 2)
Canadian Journal of Diabetes ·Ronald Goldenberg, Hannele Yki‐Järvinen, Richard M. Bergenstal, Geremia B. Bolli, M. Ziemen, Marek Wardęcki, Isabel Muehlen-Bartmer, M. Maroccia, Matthew C. Riddle
20149
13
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up
Blood Advances ·Alexander Röth, Catherine M. Broome, Wilma Barcellini, Tor Henrik Anderson Tvedt, Yoshitaka Miyakawa, Shirley D’Sa, David Cella, Sylvie Bozzi, Deepthi Jayawardene, Ronnie Yoo, Frank Shafer, Marek Wardęcki, Ilene C. Weitz
20238
14
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial
Diabetes Technology & Therapeutics ·Satish K. Garg, Karin Wernicke‐Panten, Marek Wardęcki, Daniel Kramer, François Delalande, Edward Franek, Karita Sadeharju, Travis Monchamp, P. Miossec, B.N. Mukherjee, Viral N. Shah
20207
15
Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B
EClinicalMedicine ·Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun‐ichi Nishimura, Josephine M. I. Vos, Joan Cid, Michael Storek, Nancy Wong, Ronnie Yoo, Deepthi Jayawardene, Shruti Srivastava, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome
20246
16
Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study
Blood ·Alexander Roeth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Junichi Nishimura, Josephine M. I. Vos, Michael Storek, Nancy Wong, Parija Patel, Braydon Schaible, Xiaoyu Jiang, Deepthi S. Vagge, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome
20216
17
Clinically Important Change in SF-12v2 Physical (PCS) and Mental (MCS) Component Summary Scores for Patients with Cold Agglutinin Disease: An Analysis Using the Phase 3 CARDINAL and CADENZA Studies
Blood ·Florence Joly, Mark Kosinski, Frank Shafer, Marek Wardęcki, Alia Karaouni, Quentin A. Hill
20215
18
New Insulin Glargine 300 U/mL: Efficacy and Safety of Adaptable vs. Fixed Dosing Intervals in People with T2DM
Canadian Journal of Diabetes ·Rémi Rabasa‐Lhoret, Matthew C. Riddle, Geremia B. Bolli, Phillip D. Home, Richard M. Bergenstal, M. Ziemen, Isabel Muehlen-Bartmer, Marek Wardęcki, Laetitia Vinet, Annele Yki-Järvinen
20145
19
New insulin glargine 300 U/ml: efficacy and safety of flexible vs fixed dosing intervals in people with type 2 diabetes mellitus
N. Jeandidier, MC Riddle, GB Bolli, PD Home, RM Bergenstal, M. Ziemen, Isabel Muehlen-Bartmer, Marek Wardęcki, Laetitia Vinet, H Yki-Järvinen
20145
20
Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)
Blood ·Alexander Roeth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun‐ichi Nishimura, Josephine M. I. Vos, Joan Cid, Michael Storek, Nancy Wong, Ronnie Yoo, Jennifer Wang, Deepthi S. Vagge, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome
20224

About Marek Wardęcki

Marek Wardęcki is a scholar working on Hematology, Endocrinology, Diabetes and Metabolism, Genetics, Physiology and Genetics, having authored 26 papers that have together received 721 indexed citations. Recurring topics across this work include Blood groups and transfusion (14 papers), Diabetes Management and Research (10 papers), Erythrocyte Function and Pathophysiology (7 papers), Chronic Lymphocytic Leukemia Research (4 papers), Immunodeficiency and Autoimmune Disorders (4 papers), Platelet Disorders and Treatments (4 papers), Diabetes Treatment and Management (4 papers) and Hemoglobinopathies and Related Disorders (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (482 citations), Hematology (121 citations), Surgery (127 citations), Genetics (75 citations) and Genetics (24 citations). Marek Wardęcki has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Richard M. Bergenstal, Matthew C. Riddle, Isabel Muehlen-Bartmer, M. Ziemen, Hannele Yki‐Järvinen, Emmanuelle Boëlle, Geremia B. Bolli, H Yki-Järvinen, Philip Home and Julio Rosenstock. Their work appears in journals such as Blood, Diabetes Technology & Therapeutics, Diabetes Care, Canadian Journal of Diabetes and EClinicalMedicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Parastoo DinyariBreakdown of academic impact, for papers by Krystyna JedynastyBreakdown of academic impact, for papers by Nunzia BruscaBreakdown of academic impact, for papers by Muhammad M. HafizBreakdown of academic impact, for papers by Taylor M. TrioloBreakdown of academic impact, for papers by Silvia CaprielloBreakdown of academic impact, for papers by Francesca Di CandiaBreakdown of academic impact, for papers by Ediz YeşilkayaBreakdown of academic impact, for papers by Rose GirgisBreakdown of academic impact, for papers by Shannon Fourtner